Geode Capital Management LLC Boosts Position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

Geode Capital Management LLC increased its position in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 0.9% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 428,999 shares of the specialty pharmaceutical company's stock after acquiring an additional 3,774 shares during the period. Geode Capital Management LLC owned about 2.04% of ANI Pharmaceuticals worth $23,720,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. JPMorgan Chase & Co. grew its stake in shares of ANI Pharmaceuticals by 159.3% in the third quarter. JPMorgan Chase & Co. now owns 554,835 shares of the specialty pharmaceutical company's stock worth $33,101,000 after purchasing an additional 340,854 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. grew its position in shares of ANI Pharmaceuticals by 14.6% in the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 15,442 shares of the specialty pharmaceutical company's stock valued at $854,000 after buying an additional 1,972 shares during the last quarter. Barclays PLC increased its stake in shares of ANI Pharmaceuticals by 1,681.2% in the third quarter. Barclays PLC now owns 143,033 shares of the specialty pharmaceutical company's stock valued at $8,534,000 after buying an additional 135,003 shares during the period. Franklin Resources Inc. raised its position in shares of ANI Pharmaceuticals by 6.1% during the third quarter. Franklin Resources Inc. now owns 12,057 shares of the specialty pharmaceutical company's stock worth $705,000 after acquiring an additional 691 shares during the last quarter. Finally, Victory Capital Management Inc. lifted its stake in shares of ANI Pharmaceuticals by 6.6% in the fourth quarter. Victory Capital Management Inc. now owns 13,777 shares of the specialty pharmaceutical company's stock worth $762,000 after acquiring an additional 858 shares during the period. Institutional investors and hedge funds own 76.05% of the company's stock.

Insider Activity at ANI Pharmaceuticals

In other ANI Pharmaceuticals news, SVP Krista Davis sold 1,000 shares of the stock in a transaction dated Friday, March 7th. The shares were sold at an average price of $60.86, for a total transaction of $60,860.00. Following the completion of the transaction, the senior vice president now owns 66,525 shares in the company, valued at $4,048,711.50. This trade represents a 1.48 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, VP Meredith Cook sold 400 shares of the business's stock in a transaction that occurred on Monday, April 14th. The shares were sold at an average price of $68.96, for a total transaction of $27,584.00. Following the completion of the sale, the vice president now directly owns 80,145 shares in the company, valued at approximately $5,526,799.20. This trade represents a 0.50 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 3,200 shares of company stock valued at $197,792 over the last ninety days. Corporate insiders own 12.70% of the company's stock.

ANI Pharmaceuticals Stock Up 1.5 %

Shares of ANIP traded up $1.05 on Thursday, reaching $69.42. The company's stock had a trading volume of 29,524 shares, compared to its average volume of 271,244. The stock has a market capitalization of $1.51 billion, a PE ratio of -126.22 and a beta of 0.49. The company has a current ratio of 2.74, a quick ratio of 1.97 and a debt-to-equity ratio of 1.52. ANI Pharmaceuticals, Inc. has a twelve month low of $52.50 and a twelve month high of $70.48. The firm has a fifty day moving average of $63.81 and a 200-day moving average of $59.65.

Analyst Ratings Changes

ANIP has been the subject of a number of recent analyst reports. StockNews.com downgraded shares of ANI Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Thursday. Jefferies Financial Group started coverage on shares of ANI Pharmaceuticals in a research report on Friday, March 14th. They set a "buy" rating and a $80.00 price objective for the company. Guggenheim restated a "buy" rating and issued a $86.00 target price on shares of ANI Pharmaceuticals in a report on Friday, April 11th. HC Wainwright reiterated a "buy" rating and set a $94.00 price target on shares of ANI Pharmaceuticals in a report on Monday, March 17th. Finally, Truist Financial boosted their price objective on ANI Pharmaceuticals from $62.00 to $65.00 and gave the company a "hold" rating in a research note on Monday. One investment analyst has rated the stock with a sell rating, one has given a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, ANI Pharmaceuticals has a consensus rating of "Moderate Buy" and a consensus target price of $80.13.

ANI Pharmaceuticals Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.